Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTB NASDAQ:GRCE NASDAQ:NRXP NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$2.12+1.0%$2.49$0.85▼$3.82$133.48M-0.22221,690 shs173,605 shsGRCEGrace Therapeutics$2.20-4.3%$2.88$1.79▼$5.18$34.04M0.37262,082 shs406,734 shsNRXPNRx Pharmaceuticals$3.84-2.0%$3.19$1.62▼$5.05$139.12M2.141.75 million shs594,787 shsSPRBSpruce Biosciences$51.89+5.7%$56.54$4.77▼$240.00$142.82M3.1149,433 shs80,928 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+0.95%-2.30%-13.47%-21.19%+158.85%GRCEGrace Therapeutics-4.35%-4.35%-2.22%-47.62%-22.81%NRXPNRx Pharmaceuticals-2.04%-7.25%+30.17%+106.45%+10.34%SPRBSpruce Biosciences+5.68%+2.90%-9.83%-13.60%+1,034.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$2.12+1.0%$2.49$0.85▼$3.82$133.48M-0.22221,690 shs173,605 shsGRCEGrace Therapeutics$2.20-4.3%$2.88$1.79▼$5.18$34.04M0.37262,082 shs406,734 shsNRXPNRx Pharmaceuticals$3.84-2.0%$3.19$1.62▼$5.05$139.12M2.141.75 million shs594,787 shsSPRBSpruce Biosciences$51.89+5.7%$56.54$4.77▼$240.00$142.82M3.1149,433 shs80,928 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+0.95%-2.30%-13.47%-21.19%+158.85%GRCEGrace Therapeutics-4.35%-4.35%-2.22%-47.62%-22.81%NRXPNRx Pharmaceuticals-2.04%-7.25%+30.17%+106.45%+10.34%SPRBSpruce Biosciences+5.68%+2.90%-9.83%-13.60%+1,034.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 2.86Moderate Buy$7.20239.62% UpsideGRCEGrace Therapeutics 2.00Hold$6.00172.73% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25896.09% UpsideSPRBSpruce Biosciences 2.56Moderate Buy$169.67226.97% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, NRXP, SPRB, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026SPRBSpruce Biosciences JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$135.006/5/2026SPRBSpruce Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026SPRBSpruce Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$200.00 ➝ $150.005/27/2026SPRBSpruce Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/26/2026CNTBConnect Biopharma Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/21/2026CNTBConnect Biopharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$4.005/14/2026SPRBSpruce Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$170.00 ➝ $150.005/8/2026NRXPNRx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$60K2,224.59N/AN/A$0.75 per share2.83GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ANRXPNRx Pharmaceuticals$1.23M113.11N/AN/A($0.54) per share-7.11SPRBSpruce Biosciences$4.91M29.06N/AN/A$39.72 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$55.48M-$1.15N/AN/AN/AN/A-122.29%-97.07%8/12/2026 (Estimated)GRCEGrace Therapeutics-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.51N/AN/AN/A-202.92%8/17/2026 (Estimated)SPRBSpruce Biosciences-$38.97M-$36.60N/AN/AN/AN/A-155.40%-101.67%8/13/2026 (Estimated)Latest GRCE, NRXP, SPRB, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/22/2026Q4 2026GRCEGrace Therapeutics-$0.24N/AN/AN/A$0.90 millionN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/13/2026Q1 2026SPRBSpruce Biosciences-$7.9340-$8.94-$1.0060-$8.94N/AN/A5/12/2026Q1 2026CNTBConnect Biopharma-$0.29-$0.34-$0.05-$0.34N/A$0.02 million3/31/2026Q4 2025CNTBConnect Biopharma-$0.30-$0.27+$0.03-$0.27$0.00 million($0.05) million3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.20$7.53 million$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect Biopharma0.013.233.23GRCEGrace TherapeuticsN/A14.9614.96NRXPNRx PharmaceuticalsN/A0.290.29SPRBSpruce Biosciences0.164.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%GRCEGrace Therapeutics6.08%NRXPNRx Pharmaceuticals4.27%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%GRCEGrace Therapeutics11.10%NRXPNRx Pharmaceuticals6.40%SPRBSpruce Biosciences4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11062.96 million48.73 millionOptionableGRCEGrace TherapeuticsN/A15.47 million13.76 millionN/ANRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableSPRBSpruce Biosciences202.75 million2.63 millionOptionableGRCE, NRXP, SPRB, and CNTB HeadlinesRecent News About These CompaniesSpruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS SymposiumJune 8, 2026 | businesswire.comSpruce Biosciences Announces Data Presentation at the 18th International MPS SymposiumMay 28, 2026 | businesswire.comSpruce Biosciences to Participate in Upcoming Conferences in JuneMay 27, 2026 | businesswire.comSpruce Biosciences Stockholders Approve Directors and Annual Say-on-PayMay 26, 2026 | tipranks.comSpruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | businesswire.comSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President ...May 4, 2026 | bakersfield.comBCraig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendationApril 28, 2026 | msn.comWhy is Spruce Biosciences stock sinking Tuesday?April 21, 2026 | msn.comSpruce Biosciences prices $60M public offering at $50.00 per shareApril 21, 2026 | msn.comSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | businesswire.comSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | finance.yahoo.comWall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeApril 3, 2026 | zacks.comDoes Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?March 18, 2026 | zacks.comSpruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net LossMarch 17, 2026 | insidermonkey.comSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerMarch 9, 2026 | pharmiweb.comPSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesMarch 9, 2026 | businesswire.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | insidermonkey.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | msn.comSpruce Biosciences to Present at Upcoming Investor Conferences in MarchMarch 2, 2026 | businesswire.comSPRB stock drops after company pushes back application submission timeline for experimental Sanfilippo syndrome therapyFebruary 18, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRCE, NRXP, SPRB, and CNTB Company DescriptionsConnect Biopharma NASDAQ:CNTB$2.12 +0.02 (+0.95%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.12 0.00 (-0.24%) As of 06/12/2026 05:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Grace Therapeutics NASDAQ:GRCE$2.20 -0.10 (-4.35%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$2.25 +0.05 (+2.27%) As of 06/12/2026 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.NRx Pharmaceuticals NASDAQ:NRXP$3.84 -0.08 (-2.04%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.91 +0.07 (+1.82%) As of 06/12/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Spruce Biosciences NASDAQ:SPRB$51.89 +2.79 (+5.68%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$51.10 -0.79 (-1.51%) As of 06/12/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
